Citadel Advisors’s CONMED CNMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-53,300
| Closed | -$2.51M | – | 12812 |
|
|
2025
Q3 | $2.51M | Buy |
+53,300
| New | +$2.76M | ﹤0.01% | 5623 |
|
|
2025
Q2 | – | Sell |
-2,000
| Closed | -$121K | – | 12825 |
|
|
2025
Q1 | $121K | Sell |
2,000
-3,500
| -64% | -$226K | ﹤0.01% | 11202 |
|
|
2024
Q4 | $376K | Sell |
5,500
-11,500
| -68% | -$801K | ﹤0.01% | 9187 |
|
|
2024
Q3 | $1.22M | Buy |
17,000
+11,600
| +215% | +$819K | ﹤0.01% | 6453 |
|
|
2024
Q2 | $374K | Sell |
5,400
-12,000
| -69% | -$875K | ﹤0.01% | 8654 |
|
|
2024
Q1 | $1.39M | Sell |
17,400
-17,800
| -51% | -$1.59M | ﹤0.01% | 6240 |
|
|
2023
Q4 | $3.85M | Buy |
35,200
+6,300
| +22% | +$651K | ﹤0.01% | 4189 |
|
|
2023
Q3 | $2.91M | Sell |
28,900
-900
| -3% | -$103K | ﹤0.01% | 4532 |
|
|
2023
Q2 | $4.05M | Buy |
29,800
+2,700
| +10% | +$330K | ﹤0.01% | 3968 |
|
|
2023
Q1 | $2.81M | Sell |
27,100
-33,200
| -55% | -$3.21M | ﹤0.01% | 4748 |
|
|
2022
Q4 | $5.34M | Buy |
60,300
+48,300
| +403% | +$4.01M | ﹤0.01% | 3742 |
|
|
2022
Q3 | $962K | Buy |
12,000
+9,500
| +380% | +$896K | ﹤0.01% | 7072 |
|
|
2022
Q2 | $239K | Sell |
2,500
-800
| -24% | -$96K | ﹤0.01% | 10310 |
|
|
2022
Q1 | $490K | Sell |
3,300
-4,000
| -55% | -$559K | ﹤0.01% | 9448 |
|
|
2021
Q4 | $1.03M | Buy |
7,300
+5,600
| +329% | +$793K | ﹤0.01% | 7866 |
|
|
2021
Q3 | $222K | Sell |
1,700
-1,300
| -43% | -$170K | ﹤0.01% | 11760 |
|
|
2021
Q2 | $412K | Sell |
3,000
-10,200
| -77% | -$1.4M | ﹤0.01% | 10493 |
|
|
2021
Q1 | $1.72M | Buy |
13,200
+9,600
| +267% | +$1.16M | ﹤0.01% | 6762 |
|
|
2020
Q4 | $403K | Sell |
3,600
-3,400
| -49% | -$322K | ﹤0.01% | 8555 |
|
|
2020
Q3 | $551K | Sell |
7,000
-1,800
| -20% | -$147K | ﹤0.01% | 7118 |
|
|
2020
Q2 | $634K | Buy |
8,800
+1,400
| +19% | +$97.4K | ﹤0.01% | 6641 |
|
|
2020
Q1 | $424K | Buy |
+7,400
| New | +$682K | ﹤0.01% | 6731 |
|
|
2019
Q4 | – | Sell |
-3,700
| Closed | -$356K | – | 9173 |
|
|
2019
Q3 | $356K | Sell |
3,700
-3,300
| -47% | -$310K | ﹤0.01% | 7304 |
|
|
2019
Q2 | $599K | Sell |
7,000
-1,500
| -18% | -$123K | ﹤0.01% | 6542 |
|
|
2019
Q1 | $707K | Buy |
+8,500
| New | +$618K | ﹤0.01% | 6199 |
|
|
2018
Q4 | – | Sell |
-3,300
| Closed | -$261K | – | 9167 |
|
|
2018
Q3 | $261K | Buy |
+3,300
| New | +$255K | ﹤0.01% | 7799 |
|
|
2016
Q1 | – | Sell |
-2,200
| Closed | -$97K | – | 6905 |
|
|
2015
Q4 | $97K | Buy |
2,200
+700
| +47% | +$30.4K | ﹤0.01% | 6724 |
|
|
2015
Q3 | $72K | Buy |
1,500
+500
| +50% | +$27.4K | ﹤0.01% | 7276 |
|
|
2015
Q2 | $58K | Buy |
+1,000
| New | +$53.9K | ﹤0.01% | 7562 |
|
|
2015
Q1 | – | Sell |
-2,200
| Closed | -$99K | – | 8549 |
|
|
2014
Q4 | $99K | Buy |
2,200
+200
| +10% | +$8.38K | ﹤0.01% | 6638 |
|
|
2014
Q3 | $74K | Buy |
2,000
+400
| +25% | +$15.9K | ﹤0.01% | 6641 |
|
|
2014
Q2 | $71K | Buy |
+1,600
| New | +$72.6K | ﹤0.01% | 6492 |
|
Other funds holding CNMD
VPM
VCM
CB
Citadel Advisors's CNMD Position: Q1 2026 in Review
Citadel Advisors reduced its CONMED (CNMD) stake by 61% in Q1 2026, selling an estimated $16M and leaving 246,930 shares worth $8.73M. The position accounts for ﹤0.01% of the portfolio, ranked #3444.
Citadel Advisors first reported a position in CNMD in Q3 2013 and has held it in 49 quarters since. The position peaked at $33.8M in Q4 2022. 236 funds tracked by Wall St. Rank hold CNMD as of Q1 2026.
- Citadel Advisors held 246,930 shares of CONMED worth $8.73M as of Q1 2026.
- Citadel Advisors sold 393,643 CONMED shares in Q1 2026, an estimated $16M.
- CONMED made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3444 holding.
- Citadel Advisors first reported a position in CONMED in Q3 2013 and has held it in 49 quarters since.
- Citadel Advisors's CONMED position peaked at $33.8M in Q4 2022.
- 236 funds tracked by Wall St. Rank held CONMED as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.